Bio-Techne Corporation | Mid-cap | Healthcare
$52.08
1.22%
| Bio-Techne Stock Comparison:
Bio-Techne vs VertexBio-Techne vs RegeneronBio-Techne vs Blueprint MedicinesBio-Techne vs Roivant SciencesBio-Techne vs Revolution MedicinesBio-Techne vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 1.2B
Gross Profit 769.7M 66.41%
Operating Income 242.9M 20.96%
Net Income 168.1M 14.50%
EPS (Diluted) $1.05

Balance Sheet Metrics

Total Assets 2.7B
Total Liabilities 635.0M
Shareholders Equity 2.1B
Debt to Equity 0.31

Cash Flow Metrics

Operating Cash Flow 269.0M
Free Cash Flow 236.1M

Revenue & Profitability Trend

Bio-Techne Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 1.2B 1.1B 1.1B 931.0M 738.7M
Cost of Goods Sold 389.3M 366.9M 349.1M 298.2M 255.5M
Gross Profit 769.7M 769.8M 756.5M 632.8M 483.2M
Research & Development 96.7M 92.5M 87.1M 70.6M 65.2M
Selling, General & Administrative 396.8M 352.4M 339.0M 289.9M 240.9M
Other Operating Expenses - - - - -
Other Operating Items 33.3M 33.9M 34.5M 29.6M 28.3M
Total Operating Expenses 526.8M 478.8M 460.7M 390.2M 334.3M
Operating Income 242.9M 291.0M 295.8M 242.7M 148.8M
Pre-tax Income 185.7M 338.7M 301.4M 148.2M 276.5M
Income Tax 17.6M 53.2M 38.3M 8.6M 47.2M
Net Income 168.1M 285.4M 263.1M 139.6M 229.3M
EPS (Diluted) $1.05 $1.76 $1.66 $0.87 $1.46

Income Statement Trend

Bio-Techne Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 617.4M 621.5M 605.6M 510.6M 520.9M
Non-Current Assets 2.1B 2.0B 1.7B 1.8B 1.5B
Total Assets 2.7B 2.6B 2.3B 2.3B 2.0B
Liabilities
Current Liabilities 159.4M 128.5M 176.0M 152.3M 106.7M
Non-Current Liabilities 475.6M 543.7M 417.8M 539.4M 539.7M
Total Liabilities 635.0M 672.2M 593.8M 691.7M 646.4M
Equity
Total Shareholders Equity 2.1B 2.0B 1.7B 1.6B 1.4B

Balance Sheet Composition

Bio-Techne Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 168.1M 285.4M 263.1M 139.6M 229.3M
Operating Cash Flow 269.0M 334.2M 313.7M 251.4M 350.0M
Investing Activities
Capital Expenditures -62.9M -38.2M -44.9M -44.3M -51.7M
Investing Cash Flow -210.0M -33.6M -96.9M -243.5M 27.1M
Financing Activities
Dividends Paid -50.4M -50.3M -50.2M -49.6M -48.9M
Financing Cash Flow -183.3M 612.5M -405.5M -127.6M -403.3M
Free Cash Flow 236.1M 216.1M 280.4M 307.9M 153.5M

Cash Flow Trend

Bio-Techne Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 60.87
Forward P/E 23.07
Price to Book 3.92
Price to Sales 6.55
PEG Ratio 23.07

Profitability Ratios

Profit Margin 10.89%
Operating Margin 14.10%
Return on Equity 6.53%
Return on Assets 5.24%

Financial Health

Current Ratio 3.71
Debt to Equity 20.99
Beta 1.38

Per Share Data

EPS (TTM) $0.83
Book Value per Share $12.87
Revenue per Share $7.65

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
tech 7.9B 60.87 3.92 6.53% 10.89% 20.99
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Revolution Medicines 7.5B -11.18 3.59 -36.68% 0.00% 6.46

Financial data is updated regularly. All figures are in the company's reporting currency.